The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*

Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssef, Jihad Georges, Lavin, Philip, Schoenfeld, David A., Lee, Richard A., Lenhardt, Rainer, Park, David J., Fernandez, Javier Perez, Morganroth, Melvin L., Javitt, Jonathan C., Jayaweera, Dushyantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555831/
https://www.ncbi.nlm.nih.gov/pubmed/36044317
http://dx.doi.org/10.1097/CCM.0000000000005660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555831/
https://www.ncbi.nlm.nih.gov/pubmed/36044317
http://dx.doi.org/10.1097/CCM.0000000000005660

Ejemplares similares